RxDoctor Payments Data

Annette Lavender, APRN

Family · Cincinnati, OHNPI 1710191713

Payments from drug & device makers

$11,323in general payments, 2019–2025

Across 482 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Johnson & Johnson$1K
  • Boehringer Ingelheim$1K
  • Bayer$880
  • Lilly USA, LLC$812
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$11,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,323 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$8,891
Medicare patients
54
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin58$80,043
FarxigaDapagliflozin Propanediol26$40,968
TrulicityDulaglutide21$28,379
OzempicSemaglutide15$17,987
VraylarCariprazine Hcl13$17,600
Breo ElliptaFluticasone/Vilanterol21$8,272
LantusInsulin Glargine,hum.Rec.Anlog18$1,233
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine20$1,072
Vilazodone Hcl12$1,009
Atorvastatin Calcium134$884
Valsartan13$719
Buspirone Hcl45$700
Clonidine15$681
Albuterol Sulfate HfaAlbuterol Sulfate26$598
Levothyroxine Sodium52$582

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$1,092$80,04358 claims
AstraZenecaFarxiga$1,780$40,96826 claims
Lilly USA, LLCTrulicity$812$28,37921 claims
Novo NordiskOzempic$1,626$17,98715 claims
AbbVieVraylar$553$17,60013 claims
GSKBreo Ellipta$557$8,27221 claims
Sanofi-aventis U.S. LLCLantus$183$1,23318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →